| Literature DB >> 25311424 |
Raphaël Rodriguez1, Kyle M Miller2.
Abstract
Small molecules--including various approved and novel cancer therapeutics--can operate at the genomic level by targeting the DNA and protein components of chromatin. Emerging evidence suggests that functional interactions between small molecules and the genome are non-stochastic and are influenced by a dynamic interplay between DNA sequences and chromatin states. The establishment of genome-wide maps of small-molecule targets using unbiased methodologies can help to characterize and exploit drug responses. In this Review, we discuss how high-throughput sequencing strategies, such as ChIP-seq (chromatin immunoprecipitation followed by sequencing) and Chem-seq (chemical affinity capture and massively parallel DNA sequencing), are enabling the comprehensive identification of small-molecule target sites throughout the genome, thereby providing insights into unanticipated drug effects.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25311424 DOI: 10.1038/nrg3796
Source DB: PubMed Journal: Nat Rev Genet ISSN: 1471-0056 Impact factor: 53.242